Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nanovibronix Inc (NQ: NAOV )

0.5080 -0.0025 (-0.49%)
Streaming Delayed Price Updated: 3:07 PM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Nanovibronix Inc

< Previous 1 2 3 Next >
NanoVibronix Takes Next Step to Partner with Specialist Urology Company to Expand Sales of UroShield in Germany
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Signs Letter of Intent with Potential New Distributor
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Highlights Second Quarter Revenue Growth and Narrowing of Loss from Operations in Letter to Stockholders
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Announces Commencement of UroShield Clinical Study at the University of Michigan
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Issues Letter to Stockholders
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Announces Distribution Agreement with VA Supplier CB Medical for the Distribution of UroShield
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Announces PainShield Will Be Included in Department of Veteran Affairs’ FSS Contract Award
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Issues Letter to Stockholders
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Signs Agreement for Research and Development of Next Generation PainShield and UroShield
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Featured in Your Bladder Health Magazine
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Announces Agreement for Clinical Study of UroShield at the University of Michigan
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Regains Nasdaq Compliance
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Issues Letter to Shareholders
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix UroShield Products Available on NHS Drug Tariff Effective November 1
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Gains Approval for Inclusion of UroShield Products in NHS Prescription Services’ Drug Tariff
From NanoVibronix, Inc.
Via Business Wire
BioMedNewsBreaks – IBN’s BioMedWire Highlights NanoVibronix Inc.’s (NASDAQ: NAOV) $5M Private Placement
Via Investor Brand Network
NanoVibronix Announces Presentation of Positive Independent Testing Results of UroShield at ICS Annual Meeting
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Inc. (NASDAQ: NAOV) is One of Wednesday Morning’s Most Active Stocks
Via Investor Brand Network
NanoVibronix Cites Positive Results from Independent Testing of UroShield
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Responds to CMS’ Determination for PainShield
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Applies for Inclusion of UroShield Products in NHS Prescription Services’ Drug Tariff
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Extends Distribution Agreement with Its Largest Distributor for PainShield and PainShield Plus
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Announces Distribution Agreement with Sports Medicine Supplier Mio-Guard
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Issues Letter to Shareholders
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Issues Letter to Shareholders
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Receives Positive Final Results of Independent Lifecycle Testing of PainShield Prompted by Centers for Medicare and Medicaid Services (CMS)
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Files Provisional U.S. Patent Application for UroShield Ultra
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Announces Positive Results from Independent Product Trial of UroShield for Patients with a Spinal Cord Injury
From NanoVibronix, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.